Integer (NYSE:ITGR) Updates FY24 Earnings Guidance

Integer (NYSE:ITGR) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $5.24-5.43 for the period, compared to the consensus EPS estimate of $5.30. The company issued revenue guidance of $1.707-1.727 billion, compared to the consensus revenue estimate of $1.74 billion. Integer also updated its FY 2024 guidance to 5.240-5.430 EPS.

Integer Stock Performance

NYSE:ITGR opened at $125.77 on Friday. Integer has a 1-year low of $73.40 and a 1-year high of $133.53. The stock has a market cap of $4.22 billion, a P/E ratio of 41.10, a PEG ratio of 1.80 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96. The firm has a 50-day moving average of $127.58 and a two-hundred day moving average of $120.98.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same quarter last year, the firm earned $1.27 EPS. Integer’s quarterly revenue was up 8.7% on a year-over-year basis. On average, research analysts expect that Integer will post 5.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ITGR has been the subject of several recent analyst reports. Benchmark raised their price objective on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial lowered their price objective on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday. Bank of America increased their target price on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Oppenheimer initiated coverage on Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price target for the company. Finally, Citigroup raised their price objective on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $139.75.

Insider Activity at Integer

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the sale, the director now directly owns 2,280 shares in the company, valued at approximately $272,824.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.00% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.